All News

ChatGPT,computer,learning

ICYMI: ChatGPT - A Boon or Threat to Scientific Publication?

d Jack Cush, MD

ChatGPT is a new, artificial intelligence chatbot that has dramatically changed the digital worlds of education, research, graphic design, statistics and more. While this AI driven platform has the untold potential in generating written content, there is considerable concern in assuring that human-generated content of research, education and publishing has veracity.

Read Article
inflammati.png

ICYMI: LAVLI - A New Autoinflammatory Disorder

d Jack Cush, MD

NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene (that encodes the Lyn kinase protein). They discovered that increased Lyn kinase activity promotes systemic inflammation, by altering microvascular permeability and neutrophil recruitment, while at the same time promoting hepatic fibrosis.

Read Article
computer screen safety

ICYMI: Drug Safety Differences with New Novel Therapies in RA

d Jack Cush, MD

Safety outcomes for targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs) used to treat RA were studied using data from the Anti-Rheumatic Therapies in Sweden (ARTIS) registry, showing that these newer agents are largely similar, but still have particular differences for specific infection or other adverse event risks.

Read Article
Achilles,ankle,heel

ICYMI: GRAPPA Recommendations for Treating Enthesitis in Psoriatic Arthritis

d Jack Cush, MD

GRAPPA has provided new, evidence based updates to the management of enthesitis in patients with psoriatic arthritis (PsA), affecting at least 30% of PsA patients and is associated with more severe disease, x-ray damage, and poorer outcomes. 

Read Article
eye%20exa.jpg (keep)

ICYMI: Hydroxychloroquine Dose and Risk for Incident Retinopathy

d Jack Cush, MD

A cohort study in Annals of Internal Medicine shows that higher hydroxychloroquine doses was associated with progressively greater risk for incident retinopathy. The study aimed to assess the long-term risk for incident hydroxychloroquine retinopathy and examine the degree to which average hydroxychloroquine dose within the first 5 years of treatment predicts this risk.

Read Article
RT @AurelieRheumo : The risk of osteoarticular infection following Staph aureus bacteremia is twice higher in RA (1/4) than non RA pop (1/8) Use of TNFi & orthopedic implants associated w/ OAI risk Mortality however similar in RA and non RA groups #EULAR23 POS0033

Dr. John Cush RheumNow ( View Tweet)

RT @bella_mehta : Obesity in #AOSD – predicted the development of a chronic disease course and biologic DMARD failure, 139 pts with AOSD- 19% Obese (BMI>30) observational study. abst#AB1503 #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

RT @drdavidliew : Men trying to conceive were prev told to avoid MTX. Another myth busted Why? Spermatozoa lack the FPGS enzyme responsible for MTX-PG metabolism, the tiny amount of MTX-PG in sperm isn’t active. No quality issues! OP0224 #EULAR2023 https://t.co/i4WGmoWOwU)

Links:

Dr. John Cush RheumNow ( View Tweet)

RT @Yuz6Yusof : #EULAR2023 #POS1075 Which biologics have the lowest retention rate in Elderly patients (=>65 yrs) in Rheumatoid Arthritis? Data from Italian registry showed 1/3 discontinued biologics at 2 yrs. IL6-i: lowest persistence; Abatacept: highest

Dr. John Cush RheumNow ( View Tweet)

RT @Janetbirdope : #ClinicalPearl Rx of #scleroderma #ILD -add another drug. MMF, then Cyclo, Rituximab, ?tocilizumab; if progressive fibrosis then #Nintedanib ?Pirfenidone Small RCT of MMF v Tacrolimus - looked the same -helpful if MMF fails, future pregnancy OP0240 #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

RT @Janetbirdope : A shame. Pts with #scleroderma are dying waiting for organ transplant- we should list and work them up for Tx earlier. PAH Pts May do worse @eular_org #EULAR2023 @RheumNow OP0241

Dr. John Cush RheumNow ( View Tweet)

RT @Yuz6Yusof : #EULAR2023 #POS1207 Promising therapy for dermatomyositis. Data from Stage One of Phase 2 RCT (N=18) showed Anti-IFN Beta mAb improved clinical, PROs, extra-muscular activity and reduced CK levels vs Placebo. No cases of HZV. One to watch out in the next few year

Dr. John Cush RheumNow ( View Tweet)

RT @Janetbirdope : Cool way to get peg uricase tolerated in #gout. ##Rapamycin nanoparticle Rx w SEL 212 a uricase -infusion reactions 3.4% - all premeds w steroids and antihistamines- some stomatitis - seemed to lower uric acid and have good tolerability LB0002 #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

RT @drdavidliew : Dazodalibep is the next CD40L inhibitor being tested in Sjogren’s - we need better therapies reducing symptom burden. Nice phase 2 data analyses so far of subjective measures, and plenty will be happy if we see this kind of result in phase 3 LB0003 #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

RT @Janetbirdope :What is the course of clinically suspect arthralgia in CCP+ vs neg? 781 pts, 136 got RA and sl more resolved symptoms. RA developed in both groups ACPA+ develop more rapidly -if resolution, still more MRI + vs neg. #EULAR2023 POS319. Diff patterns of progression

Dr. John Cush RheumNow ( View Tweet)

RT @Janetbirdope : I hurt because the weather is COLD! Data from Rhumadata in 14000 pt encounters show higher pt GLOBAL in winter vs summer - NB cold in Quebec #EULAR2023 POS0324. Small differences but maybe a script to go south is the right Rx!

Dr. John Cush RheumNow ( View Tweet)

RT @Yuz6Yusof : #EULAR2023 Highlights. SpA: OP0059 H2H RCT of SEC vs ADA Biosimilar in bDMARDs naive showed no difference in imaging progression at 2yrs. OP0061 Pooled analyses of UPA RCTs showed low rates of Extra-articular Manifestation. Numerically lower vs PBO for Uveitis

Dr. John Cush RheumNow ( View Tweet)

RT @bella_mehta : Diagnostic delay in #lupus is really prevalent! #EULAR2023 @RheumNow 20% with new lupus diagnosis are hospitalized! 20% diagnosis is delayed for more than 3 months!

Dr. John Cush RheumNow ( View Tweet)

RT @Janetbirdope : #SLE #EULAR recommendations What is new - use LESS #glucocorticoids, aim for none or 5 mg/d or less, use #biologics early if needed to prevent damage, #lupus #nephritis consider less pulse dose if using, voclosporin vs Belimumab ? it depends #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

RT @synovialjoints : Late Breaker - #EULAR2023 update on imaging of large vessel vasculitis. Ultrasound is now recommended as first line imaging test in all patients with suspected GCA, and axillary arteries should be in the standard examination, Dejaco C et al, Abst#LB0009

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×